Showing results (161-170 of 188) with videos related to
Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|March 1, 1996
A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancerW Jonat, A Howell, C Blomqvist, et al.Clinical Genetics|August 13, 2017
Gene-panel testing of breast and ovarian cancer patients identifies a recurrent RAD51C duplicationL M Pelttari, H Shimelis, H Toiminen, et al.Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA|September 5, 2020
Five-year follow-up results of aerobic and impact training on bone mineral density in early breast cancer patientsL Vehmanen, H Sievänen, P Kellokumpu-Lehtinen, et al.The American Journal of Cardiology|July 1, 1978
Submaximal exercise testing after acute myocardial infarction: myocardial scintigraphic and electrocardiographic observationsJ I Pulido, J Doss, D Twieg, et al.Cancer Genetics and Cytogenetics|October 20, 1999
Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumorsM Tarkkanen, S Kiuru-Kuhlefelt, C Blomqvist, et al.International Journal of Cancer|December 4, 2009
Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohortE Niméus-Malmström, A Koliadi, C Ahlin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1996
Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study GroupA Buzdar, W Jonat, A Howell, et al.European Journal of Cancer (Oxford, England : 1990)|July 19, 2000
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast groupL Hakamies-Blomqvist, M Luoma, J Sjöström, et al.British Journal of Cancer|June 27, 2002
Tumour microvessel density as predictor of chemotherapy response in breast cancer patientsO Tynninen, J Sjöström, K von Boguslawski, et al.European Journal of Vascular and Endovascular Surgery : the Official Journal of the European Society for Vascular Surgery|January 14, 2004
Lower limb amputations in Southern Finland in 2000 and trends up to 2001E Eskelinen, M Lepäntalo, E-M Hietala, et al.Pageof 19